La vendita allo scoperto per Uxin dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Uxin. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Uxin (NASDAQ:UXIN) Azioni, Report sulle vendite allo scoperto

Uxin

Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.

Uxin Limited - American Depositary Shares

Uxin Ltd

RBC Capital analyst Brian Abrahams maintains IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) with a Outperform and raises the price target from $17 to $20.

News

Price Target

Analyst Ratings

IGMS

RBC Capital Maintains Outperform on IGM Biosciences, Raises Price Target to $20

RBC Capital analyst Jon Arfstrom reiterates Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Outperform and maintains $17 price target.

Reiteration

HBAN

RBC Capital Reiterates Outperform on Huntington Bancshares, Maintains $17 Price Target

Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) shares are trading lower after the company reported&nbsp;first-quarter&nbsp;sales of&nbsp;$21.74 billion&nbsp;(-1% Y/Y),&nbsp;missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41399117/p-g-announces-fiscal-year-2025-first-quarter-results" rel="noreferrer noopener">consensus estimate of&nbsp;$21.91 billion</a>.
Organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, increased&nbsp;by 2%.
Organic sales growth was driven by a 1% increase in higher pricing and a 1% rise in organic volume, excluding the effects of acquisitions and divestitures.
Sales in the Beauty segment fell&nbsp;5%, and the Baby, Feminine &amp; Family Care segment declined 2%.
Meanwhile, the Grooming segment sales sales remained flat, while Fabric &amp; Home Care grew 1% and Health Care sales increased&nbsp;2%.
Gross profit remained flat&nbsp;at $11.3 billion. The reported gross margin expanded by 10 basis points to&nbsp;52.1%, and the core gross margin was flat year-over-year.
Gains included 170 basis points from productivity savings and 30 basis points from pricing, offset by 90 basis points from higher commodity costs, 60 basis points from unfavorable mix, and 40 basis points from product reinvestments.
Operating margin expanded 30 basis points to&nbsp;26.7% while operating income for the quarter rose 1%&nbsp;to&nbsp;$5.80 billion.
Adjusted EPS of&nbsp;$1.93 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus of&nbsp;$1.90.</a>
P&amp;G held&nbsp;$12.16 billion&nbsp;in cash and equivalents as of September 30. Operating cash flow for the quarter was&nbsp;$4.3 billion.
The company returned around $4.4&nbsp;billion&nbsp;of value to shareholders via&nbsp;$2.4 billion&nbsp;in dividend payments and&nbsp;$1.9 billion&nbsp;of share repurchases.
&#8220;We remain committed to our integrated growth strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority — across product performance, packaging, brand communication, retail execution and consumer and customer value — productivity, constructive disruption and an agile and accountable organization,&#8221; said Board Chairman, President, and CEO Jon Moeller.
Outlook: P&amp;G reaffirmed FY25 guidance for all-in sales growth of&nbsp;2%&nbsp;–&nbsp;4%&nbsp;and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">organic sales growth of&nbsp;3%&nbsp;–&nbsp;5%</a>.
This&nbsp;outlook equates to FY25 revenue of&nbsp;$85.72 billion&nbsp;–&nbsp;$87.40 billion&nbsp;(versus an estimate of&nbsp;$86.06 billion) and adjusted EPS of&nbsp;$6.91&nbsp;–<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40037468/why-gillette-parent-procter-gamble-shares-are-tumbling-today" rel="noreferrer noopener"> $7.05&nbsp;(vs. consensus of $6.97)</a>.
P&amp;G reaffirmed its outlook for adjusted free cash flow productivity of&nbsp;90%, payment of around&nbsp;$10 billion in dividends and repurchasing&nbsp;$6 billion to&nbsp;$7 billion of common shares in fiscal 2025.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYK#NYSE">IYK</a>) and Fidelity MSCI COnsumer Staples Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSTA#NYSE">FSTA</a>).
Price Action: PG shares are down 0.81% at $170.88 premarket at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41397178/procter-gamble-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earning" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

Dividends

Buybacks

Movers

FSTA

iShares Trust Dow Jones USnsumer Goods Sector Index Fund

Procter & Gamble's Mixed Bag Q1: EPS Exceeds Estimates, Reaffirms Growth Outlook & More

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and maintains $795 price target.

NFLX

Macquarie Maintains Outperform on Netflix, Maintains $795 Price Target

Biotech

General

ARQT

Arcutis Gains Health Canada Approval For ZORYVE Foam 0.3% To Treat Seborrheic Dermatitis In Patients Aged 9 And Older; Marks First New Mechanism Topical Treatment For Condition In Canada In Over 20 Years

Susquehanna analyst Biju Perincheril maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Positive and lowers the price target from $78 to $77.

Susquehanna Maintains Positive on Occidental Petroleum, Lowers Price Target to $77

~10% Shareholder Believes Proposed Sale Represents an Egregious "Take Under" and Significantly Undervalues the Company
Urges the Board to Consider Shareholders' Best Interests and Disclose the Company's 2025 Projections so Investors Can Accurately Value the Company Against the Deal Price
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVP#NASDAQ">GVP</a>) ("GSE" or the "Company"), today sent the below letter to GSE Systems' Board of Directors (the "Board") indicating its opposition to the proposed take-private merger with Pelican Energy Partners ("Pelican").
&#x2A;&#x2A;&#x2A;
GSE Systems, Inc. 6940 Columbia Gateway Drive, Suite 470 Columbia, MD 21046 Attention: The Board of Directors
October 18, 2024
Members of the Board,
I am one of GSE's largest shareholders, with an approximately 9.9% stake in the Company. After reviewing the Company's belated and limited disclosures, I believe the proposed sale to Pelican significantly undervalues the Company and puts leadership's interests ahead of shareholders' best interests.
The Board, which collectively has limited public company experience and de minimis share ownership, appears to have allowed the Company to develop liquidity issues that have become the basis for what is seemingly a fire sale. Now, with this deal, the Board is seemingly doubling down on its missteps by giving up on the Company right as the nuclear power industry is entering a renaissance that should be a significant tailwind for GSE and its prospects for enhanced value creation.
Despite GSE's apparent runway for improved financial performance, you have refused to provide a view on the business for 2025. As a result, shareholders are unable to appropriately analyze the Company's prospects and evaluate a standalone future relative to the current deal. The Board's contention that it cannot provide projections because management's forecasts have historically been unreliable simply serves as an acknowledgment of your failures when it comes to governing the business and overseeing the executive leadership you put in place.
With respect to your decision to deprive shareholders of relevant information, it is highly unusual that the Company's definitive proxy statement for the merger did not contain forward-looking business projections. I appear to be one of the many shareholders who are disappointed with this insufficient disclosure. The Company's Form-8-K filed on October 8th, 2024 – just two weeks prior to the shareholder vote – was purportedly only put out in response to "demand letters alleging similar deficiencies and/or omissions regarding the disclosures made in the Preliminary Proxy Statement or the Definitive Proxy Statement."1
In the October 8th 8-K, GSE provided a mere glimpse of very encouraging and positive projections that implied more than $0.30 of quarterly earnings for a Company that currently trades at around $4. The projections, while incomplete, appear to show that the Company is beginning to materially benefit from the nuclear resurgence. Given this context, I am calling on you to provide the market with customary disclosures regarding the Company's forward-looking projections so shareholders can make the most informed decision on the transaction. If the Company continues to provide such limited disclosures as it did in the October 8th 8-K, then it should at least reset the record date for the Pelican merger to enable the investment community to sufficiently digest this new, albeit limited, information.
While the Company's legal counsel and bankers – who stand to make millions if the deal goes through – may have signed off on the disclosures to this point, the Board should know that this deal fails the smell test. Nothing in the merger agreement prevents you from providing more information and transparency to shareholders. I believe your decision to effectively keep GSE shareholders in the dark will define your directorship at GSE and be a black mark for any of you who intend to pursue other director opportunities. Shareholders have long memories.
While you have trumpeted Institutional Shareholder Services' recent report as an endorsement, I don't believe shareholders should give it any credence. The report neglects to mention the lack of initial projections, the magnitude of the late projections and the recent trading activity indicating that shareholders believe there is more value than is being offered by Pelican. In fact, approximately 30% of the Company's outstanding shares have traded at or above the deal price this week.
In closing, I believe an independent GSE has significant upside potential. The Board failed to provide projections prior to the record date and then reluctantly offered limited disclosure just two weeks prior to the shareholder meeting. This set of circumstances, combined with a comical fairness opinion and egregious transaction expenses, are very troubling. I once again demand normal course forward projections so that shareholders, who are the owners of the business, can fairly evaluate the Pelican transaction.
Sincerely,
Bradley L. Radoff

Management

~10% Shareholder Bradley L. Radoff Issues Open Letter To GSE Systems' Board Of Directors To State Opposition To Proposed Sale To Pelican Energy Partners; Believes Proposed Sale Represents An Egregious "Take Under" And Significantly Undervalues The Company

Susquehanna analyst Biju Perincheril maintains Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) with a Neutral and raises the price target from $149 to $154.

Susquehanna Maintains Neutral on Hess, Raises Price Target to $154

Rosenblatt analyst Barton Crockett maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and raises the price target from $635 to $680.

Rosenblatt Maintains Neutral on Netflix, Raises Price Target to $680

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Overweight.

ZURA

Cantor Fitzgerald Reiterates Overweight on Zura Bio

As of Oct. 18, 2024, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">T-Mobile Us Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)</h3>
<ul>
<li>T-Mobile announced redemption of Sprint 7.625% notes due Feb. 15, 2025. The company's stock gained around 13% over the past month and has a <a href="https://www.benzinga.com/quote/TMUS">52-week high of $222.73</a>.</li>
<li>RSI Value: 82.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TMUS Price Action: Shares of T-Mobile Us gained 1% to close at $221.95 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>)</h3>
<ul>
<li>Sify Technologies will announce financial results for the second quarter on Tuesday, Oct. 22. The company's stock gained around 54% over the past month and <a href="https://www.benzinga.com/quote/SIFY">has a 52-week high</a> of $12.30.</li>
<li>RSI Value: 70.98</li>
<li>SIFY Price Action: Shares of Sify rose 14.8% to close at $3.73 on Thursday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SIFY

TMUS

Top 2 Tech And Telecom Stocks That May Crash In Q4

Susquehanna analyst Biju Perincheril maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Positive and lowers the price target from $237 to $233.

FANG

Susquehanna Maintains Positive on Diamondback Energy, Lowers Price Target to $233

One step closer to achieving public reimbursement of AMVUTTRA&#xAE; for hATTR patients in Canada
MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA&#xAE; (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).1&nbsp;This comes following a positive recommendation from the Canadian Drug Agency (CDA) and the Institut national d'excellence en santé et services sociaux (INESSS), and signals the next step in the process where individual participating provinces and territories will start to list&nbsp;AMVUTTRA&#xAE; on their formularies.

Global

ALNY

Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults

Susquehanna analyst Biju Perincheril maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Positive and lowers the price target from $63 to $62.

Susquehanna Maintains Positive on Devon Energy, Lowers Price Target to $62

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform, adjusts target to $183 from $183 (forward stock split 6:1).

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Adjusts Price Target To $183 (forward stock split 6:1)

Susquehanna analyst Biju Perincheril maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Positive and lowers the price target from $147 to $144.

Susquehanna Maintains Positive on ConocoPhillips, Lowers Price Target to $144

Cantor Fitzgerald analyst Andres Sheppard initiates coverage on PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) with a Overweight rating and announces Price Target of $14.

Initiation

Cantor Fitzgerald Initiates Coverage On PureCycle Technologies with Overweight Rating, Announces Price Target of $14

<a href="https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue" title="https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue">https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Hamas Senior Official Al-Hayya Says Group Is Continuing Path Until Achieving Palestinian People's Ambitions; Says Sinwar's Death Will Turn Into A Curse On 'The Occupiers'; Sinwar's Death Will Only Strengthen The Group; Israeli Hostages Will Not Return Until Aggression On Gaza Stops And Withdrawal Of Israeli Forces

Susquehanna analyst Biju Perincheril maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Positive and lowers the price target from $52 to $48.

Susquehanna Maintains Positive on APA, Lowers Price Target to $48

WIIM

DRUG

Bright Minds Biosciences shares are trading higher. The company announced a $35 million non-brokered private placement.

Uxin (UXIN) has released an update. Uxin Limited, a leading used car retailer in China, has announced a memorandum of understanding with Pintu (Bei...

Uxin Eyes Expansion with New Investment Proposal

Earnings week ahead: Micron, Costco, BlackBerry, Accenture and more

Uxin reports Q1 results; updates full-year outlook

Uxin reports Q1 results; initiates Q2 outlook

Uxin (UXIN) has released an update. Uxin Limited, China's prominent used car retailer, has showcased a robust financial performance for Q1 2025, wi...

Uxin Limited Reports Strong Q1 Growth and Expansion

Uxin Limited (UXIN) Q1 2025 Earnings Call Transcript

Uxin eyes EBITDA profitability ahead, posts smaller loss; shares rise

Uxin's High-Speed Pursuit Of Profit: Debt-Driven Expansion

These consumer sector stocks have seen the biggest gains off the China stimulus developments

Uxin (UXIN) has released an update. Uxin, a leading used car retailer in China, has entered a strategic partnership with Wuhan City Economic & Tech...

Uxin Forms Strategic Partnership to Expand in Wuhan

BTOC

BZUN

CAAS

CNXC

COST

CTAS

DADA

DOGZ

KNDI

LILM

MITQ

MNSO

NAPA

PRGS

RCAT

SCHL

SFIX

TOUR

UXIN

Press Releases

Uxin Announces Entry into a Term Sheet for Financing

Uxin to Report Third Quarter Fiscal Year 2024 Financial Results on April 25, 2024

Uxin Reports Unaudited Third Quarter of Fiscal Year 2024 Financial Results

Uxin Announces Strategic Partnership with Zhengzhou Airport Industry

Uxin to Report Fourth Quarter and Fiscal Year 2024 Financial Results on July 31, 2024

Uxin Reports Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

Contracts

Uxin Announces Entry into a Memorandum of Understanding for a Proposed Investment

Uxin to Report First Quarter Fiscal Year 2025 Financial Results on September 23, 2024

Uxin Reports Unaudited First Quarter of Fiscal Year 2025 Financial Results

Uxin Announces Strategic Partnership with Wuhan City Economic & Technological Development Zone

Advance Auto Parts

Asbury Automotive Gr

AutoNation

ARKO

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

AutoZone

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Uxin

Vendite allo scoperto

Uxin (NASDAQ:UXIN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO